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OBJECTIVE — Longersurvivalofpatientswithcysticﬁbrosishasincreasedtheoccurrenceof
cysticﬁbrosis–relateddiabetes(CFRD).InthisstudywedocumentedtheincidenceofCFRDand
evaluated the association between mutations responsible for cystic ﬁbrosis and incident CFRD,
while identifying potential risk factors.
RESEARCH DESIGN AND METHODS — This was a population-based longitudinal
study of 50 cystic ﬁbrosis speciality clinics in the U.K. Subjects included 8,029 individuals aged
0–64 years enrolled in the U.K. Cystic Fibrosis Registry during 1996–2005. Of these, 5,196
withdataandwithoutdiabeteswereincludedinanalysesofincidence,and3,275withcomplete
data were included in analyses of risk factors. Diabetes was deﬁned by physician diagnosis, oral
glucose tolerance testing, or treatment with hypoglycemic drugs.
RESULTS — A total of 526 individuals developed CFRD over 15,010 person-years. The
annual incidence was 3.5%. The incidence was higher in female patients and in patients with
mutations in the cystic ﬁbrosis transmembrane conductance regulator (CFTR) gene in classes I
andII.Inamultivariatemodelof377casesof3,275patients,CFTRclass(relativerisk1.70[95%
CI1.16–2.49],classIorIIversusothers),increasingage,femalesex,worsepulmonaryfunction,
liverdysfunction,pancreaticinsufﬁciency,andcorticosteroidusewereindependentlyassociated
with incident diabetes.
CONCLUSIONS — The incidence of CFRD is high in Britain. CFTR class I and II mutations
increase the risk of diabetes independent of other risk factors including pancreatic exocrine
dysfunction.
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C
onsiderable improvement in sur-
vival of patients with cystic ﬁbrosis
has led to the emergence of compli-
cations, one being cystic ﬁbrosis–related
diabetes (CFRD). Cystic ﬁbrosis, an auto-
somal recessive disease caused by the
presence on each gene of at least one of
1,500 mutations in the cystic ﬁbrosis
transmembrane conductance regulator
(CFTR), is characterized by chronic pul-
monary infections, pancreatic insufﬁ-
ciency, biliary cirrhosis, low BMI, and,
increasingly,CFRD.Theprevalenceofdi-
abetes among European children and
adults with cystic ﬁbrosis now approxi-
mates 12%, rising to 30% in adults
screened for diabetes (1–3).
Unlikethosewithtype1diabetes,pa-
tients with CFRD rarely develop ketoaci-
dosis, but like those with type 2 diabetes,
they have elements of both decreased in-
sulin secretion and sensitivity. Compared
with other types of diabetes, the risk fac-
tors for CFRD are less well characterized;
it is not entirely clear which factors differ-
entiate individuals with cystic ﬁbrosis
who do, or do not, develop diabetes.
Whereasgeneticfactorsincreasetheprev-
alence(4,5)andprobablytheincidenceof
CFRD, we do not know whether they do
so independent of other identiﬁed risk
factors.
Most observational studies of CFRD
were cross-sectional (3–7) and few pro-
spective studies exist (2,8). Risk factors
identiﬁed include, among others, female
sex, increasing age, pancreatic insufﬁ-
ciency, poor pulmonary function, organ
transplantation, elevated plasma ﬁbrino-
gen, and CFTR genotype. Cross-sectional
designs cannot exclude the possibility
that diabetes itself modiﬁes some of these
factors. The design would also obscure
the true association between any risk
factors associated with shortened survival
and CFRD (9). Likewise, no large longi-
tudinal study has evaluated genetic
factors associated with death, and, poten-
tially, incident CFRD (7).
Tosupportresearchandcareincystic
ﬁbrosis, a number of national registries
have been established, including one in
the U.K. in 1995, which is supported and
coordinated by the Cystic Fibrosis Trust.
Using data from the U.K. Cystic Fibrosis
(UKCF) Registry, in this study we esti-
mated incidence and identiﬁed risk fac-
torsforCFRD,withspeciﬁcconsideration
for CFTR mutations, from a cohort of
5,000 children and adults with cystic
ﬁbrosis.
RESEARCH DESIGN AND
METHODS—We identiﬁed 8,029 in-
dividuals aged 0–65 years entered in the
registry from 1996 to 2005. Data were
routinely collected after patient consent
in a standardized fashion from 50 British
cystic ﬁbrosis specialist centers. Of 8,029
patients, 6,678 had complete baseline
data deﬁned as registration followed
within the same calendar year by a visit
consisting of an annual review plus a
clinic visit. Of these 6,678 patients, 761
(11.4%) with diabetes were excluded. Of
the 5,917 individuals without diabetes,
721 lacked further follow-up, leaving
5,196 with at least one annual follow-up
visit, and 3,275 patients (aged 2.0–55.3
years) with complete data for all covari-
ates. Patients with complete data (com-
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From
1Addenbrooke’s Hospital, Cambridge, U.K.;
2John Radcliffe Hospital, Oxford, U.K.; the
3MRC Epi-
demiologyUnit,Cambridge,U.K.;
4PapworthHospital,Cambridge,U.K.;and
5RoyalBromptonHospital,
London, U.K.
Corresponding author: Dr. Amanda I. Adler, amanda.adler@addenbrookes.nhs.uk.
Received 5 March 2008 and accepted 28 May 2008.
Published ahead of print at http://care.diabetesjournals.org on 5 June 2008. DOI: 10.2337/dc08-0466.
© 2008 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Epidemiology/Health Services Research
ORIGINAL ARTICLE
DIABETES CARE, VOLUME 31, NUMBER 9, SEPTEMBER 2008 1789pared with those without) did not differ
by sex but were older (median 14.1 vs.
5.2 years, P  0.0001), due mainly to the
difﬁculty of acquiring pulmonary func-
tion testing in babies and young children.
End point and potential risk factors
Diabetes was deﬁned as a physician diag-
nosis of diabetes, plasma glucose values
consistentwithdiabetesfromoralglucose
tolerance testing (OGTT), or treatment
with insulin or oral hypoglycemic drugs.
Risk factors examined included age,
sex, ethnicity, age of diagnosis of cystic
ﬁbrosis, respiratory infections, BMI,
and pancreatic, hepatic, or pulmonary
dysfunction. They also included supple-
mental feeding, prior organ transplanta-
tion, corticosteroid use, and method of
detection (whether cystic ﬁbrosis was de-
tected via screening and CFTR genotype).
Ethnicitywasdeterminedbytheethnicity
of the parents. BMI was calculated as
weightinkilogramsdividedbythesquare
of height in meters. BMI z scores were
calculated using a U.K. reference popu-
lation (10). Pancreatic dysfunction was
deﬁned as use of pancreatic enzyme sup-
plementation, and hepatic dysfunction
was deﬁned as portal hypertension, ab-
normal liver function tests, or use of the
bile acids (ursodeoxycholic acid or tau-
rine). Pancreatic enzyme supplementa-
tion was expressed as total daily dose of
the lipase component and as daily dose
perkilogramofbodyweight.Supplemen-
talfeedingincludedoralsupplementsand
feeding via gastrostomy or nasogastric or
parenteral routes. An individual was con-
sidered infected with bacteria or fungi if
these were cultured from sputum at base-
line or if a physician had diagnosed
chronicinfectionfromatleasttwoisolates
in the year before baseline. Organisms in-
cluded Pseudomonas aeruginosa, Staph-
ylococcus aureus, Burkholderia cepacia,
Haemophilus inﬂuenzae, methicillin-
resistantS.aureus,andAspergillusfumigatus.
Allergic bronchopulmonary aspergillosis
(ABPA) was diagnosed clinically. Pulmo-
nary function was measured using forced
expiratory volume at 1 s (FEV1) and forced
vital capacity expressed as percentage pre-
dicted (11).
Genotypes associated with cystic ﬁ-
brosis were coded into ﬁve established
classes reﬂecting CFTR function of de-
fective production, processing, regula-
tion, conductance, and quantity of CFTR
protein(12)asfollows:I:G542X,R553X,
W1282X, R1162X, 621–1G3T, 1717–
1G3A, 1078T, and 3659C; II:
F508, I507, N1303K, and S549N; III:
G551Dand R560T; IV: R117H, R334W,
G85E,andR347P;V:38495G3A,and
A455E; and unknown: 711IG3T,
2184DA, and 1898IG3A. Patients
with two alleles within the same class or
only one allele typed were assigned that
class. Heterozygotes for F508 were as-
signed the class of the non-F508 allele
(13).
Statistics
Incidence rates for CFRD were calculated
as the number of new cases divided by
follow-up time among the 5,196 patients
with baseline and follow-up data and
stratiﬁed by 10-year age-groups and sex.
In this retrospective cohort, follow-up
time lasted from registration to the ﬁrst
detection of diabetes or censoring and is
expressed in person-years.
Among the 3,275 individuals with
complete data, we tested differences be-
tween patients who did and did not de-
velopdiabeteswith
2testsforcategorical
variables and t tests or Kruskal-Wallis
testsfornormallyornonnormallydistrib-
uted continuous variables. Proportional
hazardsmodelingidentiﬁedpotentialrisk
factors. For categorical variables, we eval-
uated proportional hazards assumptions
using Kaplan-Meyer survival curves. We
chose variables for multivariate modeling
if they were associated with CFRD in uni-
variate analyses at P  0.05. Age at base-
line, BMI, BMI z score, and FEV1 were
coded as continuous. Binary variables in-
cluded sex, ethnicity (at least one non-
white parent versus two white parents),
hepatic dysfunction, supplemental feed-
ing, respiratory infections, ABPA, oral
pancreatic enzyme supplementation, and
corticosteroid use (oral and/or inhaled)
within the year before registration. Age of
diagnosis of cystic ﬁbrosis and dose of
pancreaticenzymesupplementationwere
coded as binary variables around the me-
dians. We coded CFTR genotype by class
asdescribedandasabinaryvariable(class
I–II vs. III–V). One-way interactions be-
tweengenotypeorsexandothervariables
were tested. We calculated hazard ratios
(expressed as relative risks [RRs]) with
95% CIs. We performed database manip-
ulations using Cache ´ (InterSystems,
2007) and statistical analyses using R (R
Development Core Team, 2007).
RESULTS—The median age of the co-
hort was 12.0 years (interquartile range
6.0–19.8);54%weremaleand96%were
white. The characteristics of the study
population and of those who did or did
not develop CFRD are shown (Table 1).
Incidence
Of 5,196 patients, 526 developed diabe-
tes during 15,010 person-years of fol-
low-up (median 2.67 years, range 0.08–
8.33 years). In 40% (211 patients),
diabetes was diagnosed on the basis of
insulin use, in 22% (117 patients) from
OGTT results, in 4% (20 patients) on the
basis of use of oral hypoglycemic drugs,
andin1%(5patients)byaphysician.The
remainder met multiple criteria. The inci-
denceofdiabeteswas3.5%peryear.Dur-
ing follow-up, 202 patients died without
having the diagnosis of diabetes.
The incidence rose with age, was
higher in female patients up to age 40,
and declined after age 40 for both men
and women. Annual incidence rose from
1 to 2% in the ﬁrst decade to 6t o7 %i n
the fourth decade (Fig. 1).
Risk factors
Patients with class I mutations had the
highest incidence of CFRD, and those
with class V mutations had the lowest in-
cidence(Fig.2).Theincidencewassignif-
icantly higher in individuals with class I
or II relative to III to V mutations (P 
0.01). In univariate analyses, patients
with incident CFRD were less likely to
have been screened for cystic ﬁbrosis and
more likely to have infections, to have
liver or pulmonary function abnormali-
ties, and to have used corticosteroids or
pancreatic enzyme replacement. The me-
dian FEV1 in patients who developed
CFRD was 57.8% compared with 75.3%
in those who did not (P  0.0001). Ad-
justed for age and/or sex, FEV1 re-
mained strongly inversely associated
with incident CFRD. BMI was higher
and BMI z scores were lower in those
who developed diabetes than in those
who did not (Table 1).
In a multivariate model, increasing
age, female sex, decreasing FEV1, liver
dysfunction, pancreatic enzyme replace-
ment, corticosteroids use, and CFTR ge-
netic class were independently associated
withincidentdiabetes.CFTRclassIandII
compared with III to IV was associated
with a RR of 1.70. Female patients were
60% more likely to develop diabetes
thanmalepatients,andeachyearofageor
percent decrease in predicted FEV1 was
associated with a 2–3% increase in risk
(Table 2). Diagnosis of cystic ﬁbrosis by
screening, pulmonary infections, supple-
mental feeding, and BMI or BMI z score
Cystic ﬁbrosis–related diabetes
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variate modeling. There were no signiﬁ-
cant interactions. After exclusion of 334
individuals not taking pancreatic en-
zymes, a multivariate model (362 cases
among 2,931 patients) showed no associ-
ation between the dosage of pancreatic
enzyme replacement and CFRD.
CONCLUSIONS —This large, longi-
tudinal, registry-based study documents
a high incidence of CFRD among individ-
uals with cystic ﬁbrosis in Britain and
demonstrates that CFTR mutation class
independently increases risk. The study
also conﬁrms the fact that female patients
are at higher risk for CFRD, which is not
accounted for by a higher prevalence of
risk factors in female patients. The study
also conﬁrms the independent associa-
tions of poor hepatic and pulmonary
functionandofuseofpancreaticenzymes
or corticosteroids with CFRD.
Few studies of CFRD incidence exist.
Theannualincidenceof3.5%wereportis
similar to the 3.8% reported from a Dan-
ish study of fewer than 200 patients (2).
Based on extremely small numbers (12
and 6 incident cases of CFRD) and de-
rived from cumulative incidence values,
Italian (8) and Greek (14) investigators
show a CFRD annual incidence of
4.0%. The high incidence of CFRD in
the ﬁrst decade in this study suggests that
screening for diabetes in this age-group,
although not currently recommended in
the U.K., may be justiﬁed. Whether indi-
vidualswithscreen-detecteddiabetesfare
better has not been determined.
CFTR protein regulates the function
of chloride channels on the apical mem-
braneofepithelialcellsandhelpsregulate
transepithelial transport of other ions and
water. The grouping of mutations into
functional categories is as follows: class I,
Table 1—Characteristics of patients at baseline stratiﬁed by development of diabetes
Parameter All patients Did not develop diabetes Incident diabetes P value
n 3,275 2,898 377
Age (years) 14.1 (9.2–21.1) 13.5 (8.9–20.5) 18.0 (12.4–25.4) 0.0001
Sex (female) 1,491 (45.5) 1,288 (44.4) 203 (53.8) 0.001
Ethnicity (white) 3,166 (96.7) 2,797 (96.5) 369 (97.9) NS
BMI (kg/m
2) 18.6 (16.4–21.3) 18.5 (16.3–21.3) 19.2 (17.3–21.4) 0.001
BMI z score 0.15 (0.86 to 0.56) 0.10 (0.81 to 0.59) 0.49 (1.23 to 0.22) 0.0001
FEV1 (% predicted) 72.9 (53.0–91.3) 75.3 (55.3–92.7) 57.8 (36.9–74.5) 0.0001
Forced vital capacity (% predicted) 82.6 (68.0–94.1) 83.6 (69.6–95.3) 73.3 (57.1–86.9) 0.0001
Any use of pancreatic enzyme 2,941 (89.8) 2,579 (89.0) 362 (96.0) 0.01
Lipase dose (units/day) 250,000 (150,000–400,000) 250,000 (150,000–400,000) 300,000 (184,000–500,000) 0.0001
Lipase dose (units   kg body
weight
1   day
1) 6,829 (3,464–10,200) 6,828 (3,448–10,150) 6,865 (3,602–10,560) NS
Supplemental feeding 1,439 (43.9) 1,236 (42.7) 203 (53.8) 0.0001
Oral corticosteroids 313 (9.6) 263 (9.1) 50 (13.3) 0.012
Any corticosteroids use 1,761 (53.8) 1,526 (52.7) 235 (62.3) 0.001
Former organ transplantation 44 (1.3) 37 (1.3) 7 (1.9) NS
Abnormal liver function tests 406 (12.4) 342 (11.8) 64 (16.9) 0.01
Use of ursodeoxycholic acid or
taurine 534 (16.3) 455 (15.7) 79 (21.0) 0.012
Any hepatic dysfunction 719 (28.1) 610 (21.0) 109 (28.9) 0.001
P. aeruginosa 1,925 (58.8) 1,651 (57.0) 274 (72.7) 0.0001
B. cepacia 151 (4.6) 129 (4.5) 22 (5.8) NS
S. aureus 1,379 (42.1) 1,223 (42.2) 156 (41.4) NS
H. inﬂuenzae 668 (20.4) 605 (20.9) 63 (16.7) NS
A. fumigatus 341 (10.2) 301 (10.2) 40 (10.6) NS
Methicillin-resistant S. aureus 46 (1.4) 40 (1.4) 6 (1.6) NS
ABPA 197 (6.0) 178 (6.1) 19 (5.0) NS
CFTR mutation class 0.01
I 266 (8.1) 227 (7.8) 39 (10.3)
II 2,608 (79.6) 2,299 (79.3) 309 (82.0)
III 256 (78.2) 231 (8.0) 25 (6.6)
IV 125 (3.8) 121(4.2) 4 (1.1)
V 20 (0.6) 20 (0.7) 0 (0)
Unknown 0 (0) 0 (0) 0 (0)
CFTR mutation class I or II 2,874 (87.7) 2,526 (87.2) 348 (92.3) 0.01
Age at diagnosis of cystic ﬁbrosis
(years) 0.4 (0.08–2.5) 0.4 (0.08–2.5) 0.5 (0.08–2.0) NS
Cystic ﬁbrosis detected by
screening 377 (11.5) 349 (12.0) 28 (7.4) 0.011
Data are absolute values (medians) or n (%) for continuous variables with interquartile range and percentages for categorical variables. P values represent difference
between groups using Kruskal-Wallis tests for continuous variables and 
2 tests for categorical variables.
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tion of CFTR in the endoplasmic reticu-
lum; class III, transport of CFTR to the
cell membrane, but no appropriate re-
sponse; class IV, diminished action of
CFTR in the cell membrane; and class V,
normal but inadequate amounts of CFTR
(12). Many studies document associa-
tions between functional class and com-
plications of cystic ﬁbrosis, including
pancreatic dysfunction (13,15). This
study shows an association between class
and CFRD adjusted for pancreatic exo-
crine function as measured by pancreatic
enzyme replacement. Investigators have
previously searched for genes in CFRD,
concentrating either on those associated
with type 2 diabetes and inﬂammation or
with cystic ﬁbrosis. F508 homozygosity
was associated with CFRD in some, but
not all, studies (3,16–19). A prospective
study comprising few patients with inci-
dent diabetes (n  12) (8) showed that
patients homozygous for F508 were
more likely to develop diabetes. A large
U.S. registry-based cross-sectional study
reported an association of F508 ho-
mozygosityandCFRDbutpresentedonly
univariateresults(4).AEuropeanregistry
studydocumentedagreaterprevalenceof
diabetes in adults among class II (282 of
1,276, 22.1%) mutations than in class IV
mutations (1 of 65, 1.5%); however, no
statistical testing was performed, and no
incidence rate was calculated (5). The
present study included 377 patients with
CFRD, controlled for confounding fac-
tors, and, being longitudinal, accounted
in part for competing risks (13). It could
not, however, determine whether the risk
factors caused diabetes.
Genotype may predispose to diabetes
via pancreatic dysfunction or may play a
moredirectrole.CFRDresultsmorefrom
decreased 	-cell function than from de-
creased insulin sensitivity (19). This ﬁnd-
ing supports a function for CFTR in
pancreatic islets where, in rats, investiga-
tors have identiﬁed CFTR mRNA (20). In
mice made diabetic by streptozotocin,
those who were CFTR-null (/) had
higher blood glucose levels than other
mice; the investigators concluded that is-
let dysfunction is inherent to the
CFTR
/ state (21). CFTR has also been
identiﬁed in the human hypothalamus,
(22), where it may play a role in glucose
regulation.
Whether pancreatic exocrine dys-
function mirrors pancreatic endocrine
dysfunction is not clear. Investigators
have found pancreatic exocrine dysfunc-
tion in both type 2 and type 1 diabetes. In
cystic ﬁbrosis, clinicians adjust doses of
pancreatic enzyme to enable patients to
eat a diet containing fat and diminish gas-
trointestinalsymptoms.However,studies
in cystic ﬁbrosis have shown both under-
and overtreatment with pancreatic en-
zymes relative to native pancreatic func-
tion (23). The strong association between
pancreatic enzyme use and incident dia-
Figure 1—Incidence of CFRD per 100 person-years by age and sex. Vertical bars represent 95%
conﬁdence limits; f, male patients; u, female patients.
Figure 2—Incidence of CFDR per 100 person-years by class of CFTR mutation. Vertical bars
represent 95% conﬁdence limits.
Cystic ﬁbrosis–related diabetes
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use is likely to be a good marker of pan-
creatic function but may itself increase
risk.
The association between female sex
andCFRDiswelldescribed(4)anddiffers
from that for type 1 or 2 diabetes. Earlier
puberty with glucose intolerance has
beenproposedasanexplanation(24)and
may in part account for our ﬁndings be-
cause incidence in female patients rose
between age 5 and 10 (not shown). Yet,
the female predominance persists beyond
puberty.Theabsenceofafemalepredom-
inance at age 30 suggests that women
susceptible to diabetes will have devel-
oped it or may have died.
An association between poor pul-
monary function and CFRD has been
reported from cross-sectional studies
(4–6), and other studies have demon-
strated accelerated decline in pulmonary
functionbeforediagnosisofCFRD(2,25).
In cystic ﬁbrosis, it is possible that pre-
diabetic (or prediagnostic) states worsen
pulmonaryfunction.Inthepresentstudy,
poor pulmonary function preceded dia-
betes and was independent of age, sex,
genotype, medical interventions, and
other cystic ﬁbrosis–related complica-
tions. Individuals with diabetes (but
without cystic ﬁbrosis) have lung pa-
renchymal histological changes includ-
ing thickened basement membrane,
ﬁbrosis, and septal obliteration (26),
suggesting a direct deleterious effect of
hyperglycemia.
Other results are notable. Although
cystic ﬁbrosis is characterized by a low
BMI, this did not itself increase the risk of
diabetes.Corticosteroidusewasindepen-
dentlyassociatedwithdiabetes,butABPA
and organ transplantation, both indica-
tionsforcorticosteroids,werenot,evenin
univariate analyses.
This study’s strength was the use of
longitudinal, national, and systematically
collected data. With respect to possible
biases related to incidence rates, the true
incidence of CFRD in Britain may be
higher than we report for three reasons.
First, the calculation of time-to-diabetes
overestimated true values because pa-
tients developed diabetes before their
clinic visits. Second, not all individuals
werescreenedfordiabetes.TheU.K.Cys-
tic Fibrosis Trust recommends annual
OGTTs during periods of clinical stability
(17), and 85% (20 of 23) of adult cen-
tersscreenfordiabetes.Forpediatriccen-
ters, screening is recommended at age
12. Last, patients excluded from analy-
sis of incidence were older (1 year) and
had worse pulmonary function (FEV1
2% lower) and, therefore, were at
higherriskforCFRD.Althoughincidence
rates derived from registries may be less
reliable than those from cohort studies,
frequent follow-up of patients with cystic
ﬁbrosis in the U.K. (because of disease
severity and free care) diminishes this
possibility. Despite a longitudinal design,
theRRwereportforgenotypemayunder-
estimate the true value if patients at high
risk for diabetes died before registration
orwerelesslikelytoundergogenotyping.
For each of the variables (genotype, cor-
ticosteroid use, pancreatic enzyme re-
placement, poor pulmonary function,
and poor hepatic function), ascertain-
ment bias is possible. If sicker patients
had more frequent clinical visits, then
their physicians may have been more
likely to diagnose diabetes, and this
would mean that the RRs we report over-
estimate true values.
In summary, this study documents
the high incidence of diabetes in cystic
ﬁbrosis and the fact that CFTR mutation
class inﬂuences the risk of diabetes inde-
pendent of other risk factors. It suggests
that screening for diabetes may be mer-
itedacrosstheagespectrum.Byestablish-
ingage-speciﬁcincidencerates,thisstudy
providesusefulinformationtohealthcare
providers, disease modelers, and clinical
trialists. Finally, by identifying risk fac-
tors, this study may help us better under-
stand the pathogenesis of CFRD.
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